A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies
详细信息 查看全文
- 作者：Hisashi Yamamoto1 ; Naoyuki Uchida1 ; 2 ; nuchida@toranomon.gr.jp" class="auth_mail" title="E-mail the corresponding author ; Mitsuhiro Yuasa1 ; Kosei Kageyama1 ; Hikari Ota1 ; Daisuke Kaji1 ; Aya Nishida1 ; Kazuya Ishiwata1 ; Shinsuke Takagi1 ; Masanori Tsuji1 ; Yuki Asano-Mori1 ; Go Yamamoto1 ; Koji Izutsu1 ; 2 ; Kazuhiro Masuoka1 ; Atsushi Wake1 ; Akiko Yoneyama3 ; Shigeyoshi Makino4 ; Shuichi Taniguchi1 ; 2
- 关键词：Reduced-toxicity myeloablative regimen ; Intravenous busulfan ; Cord blood transplantation
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：22
- 期：10
- 页码：1844-1850
- 全文大小：360 K
文摘
- •
A novel myeloablative regimen in cord blood transplantation was investigated for patients with active diseases
- •
The regimen provided reliable engraftment and durable remission with acceptable nonrelapse mortality
- •
Overall survival and progression-free survival were both estimated as 54.9% at 2 years after transplantation